REVIEW

You have free access to this content

Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice

Joana M. Gil-Mohapel

Article first published online: 16 FEB 2011

DOI: 10.1111/j.1755-5949.2011.00246.x

Issue

CNS Neuroscience & Therapeutics

Volume 18, Issue 1, pages 77–86, January 2012

Additional Information

How to Cite

Gil-Mohapel, J. M. (2012), Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice. CNS Neuroscience & Therapeutics, 18: 77–86. doi: 10.1111/j.1755-5949.2011.00246.x

Author Information

Division of Medical Sciences, Island Medical Program, University of Victoria, Victoria, British Columbia, Canada

^*Joana M. Gil-Mohapel, Ph.D., Division of Medical Sciences, Island Medical Program, University of Victoria, Victoria, BC, V8W 2Y2, Canada. Tel.: +1.250.472-5547; Fax: +1.250.472-5505; E-mail: jgil@uvic.ca

Publication History

Issue published online: 26 JAN 2012
Article first published online: 16 FEB 2011

ARTICLE TOOLS

View Full Article (HTML) Get PDF (591K)

References

1
Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 2004;5:373–384.
2
Gil JM, Rego AC. The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease. Brain Res Rev 2009;59:410–431.
3
Hickey MA, Chesselet MF. The use of transgenic and knock-in mice to study Huntington's disease. Cytogenet Genome Res 2003;100:276–286.
4
Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493–506.
5
Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 2000;97:8093–8097.
6
Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci 2003;23:2193–2202.
7
Stack EC, Kubilus JK, Smith K, et al. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol 2005;490:354–370.
Direct Link:
8
Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008;27:2803–2820.
Direct Link:
9
Gray M, Shirasaki DI, Cepeda C, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 2008;28:6182–6195.
10
Spampanato J, Gu X, Yang XW, Mody I. Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience 2008;157:606–620.
11
Hodgson JG, Agopyan N, Gutekunst CA, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999;23:181–192.
12
Slow EJ, van Raamsdonk J, Rogers D, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003;12:1555–1567.
13
Wellington CL, Ellerby LM, Hackam AS, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998;273:9158–9167.
14
Wellington CL, Ellerby LM, Gutekunst CA, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci 2002;22:7862–7872.
15
Gafni J, Ellerby LM. Calpain activation in Huntington's disease. J Neurosci 2002;22:4842–4849.
16
Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM. Inhibition of calpain cleavage of huntingtin reduces toxicity: Accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 2004;279:20211–20220.
17
Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006;125:1179–1191.
18
Graham RK, Slow EJ, Deng Y, et al. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol Dis 2006;21:444–455.
19
Van Raamsdonk JM, Pearson J, Bailey CD, et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 2005;95:210–220.
Direct Link:
20
Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci 2005;25:4169–4180.
21
Van Raamsdonk JM, Murphy Z, Selva DM, et al. Testicular degeneration in Huntington disease. Neurobiol Dis 2007;26:512–520.
22
Pouladi MA, Graham RK, Karasinska JM, et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 2009;132:919–932.
23
Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet 2005;14:3823–3835.
24
Slow EJ, Graham RK, Osmand AP, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci USA 2005;102:11402–11407.
25
Graham RK, Pouladi MA, Joshi P, et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 2009;29:2193–2204.
26
Benn CL, Slow EJ, Farrell LA, et al. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience 2007;147:354–372.
27
Milnerwood AJ, Raymond LA. Corticostriatal synaptic function in mouse models of Huntington's disease: Early effects of huntingtin repeat length and protein load. J Physiol 2007;585:817–831.
Direct Link:
28
Joshi PR, Wu NP, André VM, et al. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 2009;29:2414–2427.
29
DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990–1993.
30
Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537–548.
31
Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998;95:55–66.
32
Kuemmerle S, Gutekunst CA, Klein AM, et al. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 1999;46:842–849.
Direct Link:
33
Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431:805–810.
34
Van Raamsdonk JM, Gibson WT, Pearson J, et al. Body weight is modulated by levels of full-length huntingtin. Hum Mol Genet 2006;15:1513–1523.
35
Pouladi MA, Xie Y, Skotte NH, et al. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet 2010;19:1528–1538.
36
Van Raamsdonk JM, Pearson J, Rogers DA, et al. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 2005;14:1379–1392.
37
Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neurosci 2006;7:80–89.
38
Fernandes HB, Baimbridge KG, Church J, Hayden MR, Raymond LA. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J Neurosci 2007;27:13614–13623.
39
Cowan CM, Fan MM, Fan J, et al. Polyglutamine-modulated striatal calpain activity in YAC transgenic Huntington disease mouse model: Impact on NMDA receptor function and toxicity. J Neurosci 2008;28:12725–12735.
40
Okamoto S, Pouladi MA, Talantova M, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 2009;15:1407–1413.
41
Milnerwood AJ, Gladding CM, Pouladi MA, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010;65:178–190.
42
Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl 2004;68:117–122.
43
Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 2007;13:453–444.
44
Tang TS, Slow E, Lupu V, et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci USA 2005;102:2602–2607.
45
Tang TS, Tu H, Chan EY, et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003;39:227–239.
46
Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J Neurosci 2009;29:1257–1266.
47
Kim YC, Kim SR, Markelonis GJ, Oh TH. Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamate-induced neurodegeneration. J Neurosci Res 1998;53:426–432.
Direct Link:
48
Kim S, Ahn K, Oh TH, Nah SY, Rhim H. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem Biophys Res Commun 2002;296:247–254.
49
Lian XY, Zhang Z, Stringer JL. Protective effects of ginseng components in a rodent model of neurodegeneration. Ann Neurol 2005;57:642–648.
Direct Link:
50
Kim JH, Kim S, Yoon IS, et al. Protective effects of ginseng saponins on 3-nitropropionic acid-induced striatal degeneration in rats. Neuropharmacology 2005;48:743–756.
51
Wu J, Jeong HK, Bulin SE, Kwon SW, Park JH, Bezprozvanny I. Ginsenosides protect striatal neurons in a cellular model of Huntington's disease. J Neurosci Res 2009;87:1904–1912.
Direct Link:
52
Kahlem P, Green H, Djian P. Transglutaminase action imitates Huntington's disease: Selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell 1998;1:595–601.
53
Lesort M, Chun W, Johnson GV, Ferrante RJ. Tissue transglutaminase is increased in Huntington's disease brain. J Neurochem 1999;73:2018–2027.
54
Karpuj MV, Becher MW, Steinman L. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem Int 2002;40:31–36.
55
Mastroberardino PG, Iannicola C, Nardacci R, et al. ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 2002;9:873–880.
56
Bailey CD, Johnson GV. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J Neurochem 2005;92:83–92.
Direct Link:
57
Bailey CD, Johnson GV. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 2006;27:871–879.
58
Melino G, Annicchiarico-Petruzzelli M, Piredda L, et al. Tissue transglutaminase and apoptosis: Sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol 1994;14:6584–6596.
59
Piacentini M, Farrace MG, Piredda L, et al. Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress. J Neurochem 2002;81:1061–1072.
Direct Link:
60
Oliverio S, Amendola A, Rodolfo C, Spinedi A, Piacentini M. Inhibition of ‘tissue’ transglutaminase increases cell survival by preventing apoptosis. J Biol Chem 1999;274:34123–34128.
61
Chun W, Lesort M, Tucholski J, Ross CA, Johnson GV. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates. J Cell Biol 2001;153:25–34.
62
Igarashi S, Koide R, Shimohata T, et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 1998;18:111–117.
63
de Cristofaro T, Affaitati A, Cariello L, Avvedimento EV, Varrone S. The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates. Biochem Biophys Res Commun 1999;260:150–158.
64
Ientile R, Campisi A, Raciti G, et al. Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells. J Neurosci Res 2003;74:52–59.
Direct Link:
65
Zainelli GM, Dudek NL, Ross CA, Kim SY, Muma NA. Mutant huntingtin protein: A substrate for transglutaminase 1, 2, and 3. J Neuropathol Exp Neurol 2005;64:58–65.
66
Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002;22:8942–8950.
67
Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002;8:143–149.
68
Wang X, Sarkar A, Cicchetti F, et al. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci 2005;231:57–66.
69
Fox JH, Barber DS, Singh B, et al. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem 2004;91:413–422.
Direct Link:
70
Lesort M, Lee M, Tucholski J, Johnson GV. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003;278:3825–3830.
71
Borrell-Pagès M, Canals JM, Cordelières FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006;116:1410–1424.
72
Pinto JT, Van Raamsdonk JM, Leavitt BR, et al. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: Implications for the treatment of Huntington disease. J Neurochem 2005;94:1087–1101.
Direct Link:
73
Dubinsky R, Gray C. CYTE-I-HD: Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov Disord 2006;21:530–533.
Direct Link:
74
Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997;120:503–514.
75
Bohnen NI, Koeppe RA, Meyer P, et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology 2000;54:1753–1759.
76
Oyanagi K, Takeda S, Takahashi H, Ohama E, Ikuta F. A quantitative investigation of the substantia nigra in Huntington's disease. Ann Neurol 1989;26:13–19.
Direct Link:
77
Yohrling GJ 4th, Jiang GC, DeJohn MM, et al. Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. Brain Res Mol Brain Res 2003;119:28–36.
78
Huot P, Lévesque M, Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 2007;130:222–232.
79
Gutekunst CA, Li SH, Yi H, et al. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J Neurosci 1999;19:2522–2534.
80
Augood SJ, Faull RL, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 1997;42:215–221.
Direct Link:
81
Cha JH, Kosinski CM, Kerner JA, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA 1998;95:6480–6485.
82
van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 2005;65:941–943.
83
Charvin D, Vanhoutte P, Pages C, Borrelli E, Caboche J. Unraveling a role for dopamine in Huntington's disease: The dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci USA 2005;102:12218–12223.
84
Cyr M, Sotnikova TD, Gainetdinov RR, Caron MG. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J 2006;20:2541–2543.
85
Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: A review. Neurotox Res 2000;1:181–195.
- CrossRef,
- PubMed,
- CAS
86
Phillips W, Barker R. The use of tetrabenazine in movement disorders. Adv Clin Neurosci Rehabil 2005;5:40–41.
87
Tang TS, Chen X, Liu J, Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 2007;27:7899–7910.
88
Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology 2006;66:366–372.
89
Savani AA, Login IS. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology 2007;68:797.
90
Warby SC, Doty CN, Graham RK, et al. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum Mol Genet 2008;17:2390–2404.
91
Warby SC, Doty CN, et al. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 2009;40:121–127.
92
Kim YJ, Yi Y, Sapp E, et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 2001;98:12784–12789.
93
Hermel E, Gafni J, Propp SS, et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 2004;11:424–438.
94
Wellington CL, Singaraja R, Ellerby L, et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem 2000;275:19831–19838.
95
Clifford JJ, Drago J, Natoli AL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002;109:81–88.
96
Suzuki T, Fukuo K, Suhara T, et al. Eicosapentaenoic acid protects endothelial cells against anoikis through restoration of cFLIP. Hypertension 2003;42:342–348.
97
Babcock T, Helton WS, Espat NJ. Eicosapentaenoic acid (EPA): An antiinflammatory omega-3 fat with potential clinical applications. Nutrition 2000;16:1116–1118.
98
Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004;6:461–467.
- CrossRef,
- PubMed
99
Madsen L, Frøyland L, Kryvi H, et al. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J Lipid Res 1997;38:1851–1858.
- PubMed,
- Web of Science® Times Cited: 96
100
Van Raamsdonk JM, Pearson J, Rogers DA, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 2005;196:266–272.
101
Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: A double-blind, randomized placebo-controlled trial. Neurology 2005;65:286–292.
102
Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000;97:6763–6768.
103
Schaffar G, Breuer P, Boteva R, et al. Cellular toxicity of polyglutamine expansion proteins: Mechanism of transcription factor deactivation. Mol Cell 2004;15:95–105.
104
Li SH, Cheng AL, Zhou H, et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 2002;22:1277–1287.
105
Dunah AW, Jeong H, Griffin A, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002;296:2238–2243.
106
Goellner GM, Rechsteiner M. Are Huntington's and polyglutamine-based ataxias proteasome storage diseases? Int J Biochem Cell Biol 2003;35:562–571.
107
Gunawardena S, Goldstein LS. Polyglutamine diseases and transport problems: Deadly traffic jams on neuronal highways. Arch Neurol 2005;62:46–51.
108
Miller TW, Messer A. Intrabody applications in neurological disorders: Progress and future prospects. Mol Ther 2005;12:394–401.
109
Messer A, McLear J. The therapeutic potential of intrabodies in neurologic disorders: Focus on Huntington and Parkinson diseases. BioDrugs 2006;20:327–333.
110
Lecerf JM, Shirley TL, Zhu Q, et al. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 2001;98:4764–4769.
111
Colby DW, Chu Y, Cassady JP, et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci USA 2004;101:17616–17621.
112
Miller TW, Zhou C, Gines S, et al. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol Dis 2005;19:47–56.
113
Murphy RC, Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Brain Res Mol Brain Res 2004;121:141–145.
114
Wolfgang WJ, Miller TW, Webster JM, et al. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA 2005;102:11563–11568.
115
McLear JA, Lebrecht D, Messer A, Wolfgang WJ. Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease. FASEB J 2008;22:2003–2011.
116
Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 2009;29:13589–13602.

View Full Article (HTML) Get PDF (591K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice

CNS Neuroscience & Therapeutics

How to Cite

Author Information

Publication History

ARTICLE TOOLS

References

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice

CNS Neuroscience & Therapeutics

How to Cite

Author Information

Publication History

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

References

More content like this